Orexo AB
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- Public
- Established
- 1995-01-01
- Employees
- 116
- Market Cap
- -
- Website
- http://www.orexo.se
OXD01 in Combination With Sublingual Buprenorphine/Naloxone for Treatment of Opioid Use Disorder
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-07-01
- Last Posted Date
- 2023-08-07
- Lead Sponsor
- Orexo AB
- Target Recruit Count
- 437
- Registration Number
- NCT04948307
- Locations
- 🇺🇸
Patient First Medical Clinic, Dearborn, Michigan, United States
🇺🇸Parkway Medical Center, Birmingham, Alabama, United States
🇺🇸North County Clinical Research, Oceanside, California, United States
Efficacy of BNX Sublingual Tablets Versus BNX Sublingual Film for Treatment of Opioid-Dependent Adults
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-07-26
- Last Posted Date
- 2017-05-10
- Lead Sponsor
- Orexo AB
- Target Recruit Count
- 759
- Registration Number
- NCT01908842
Multi-Center, Open-Label, 24-Week Study of OX219 Safety and Efficacy for Maintenance Treatment of Opioid Dependence
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-07-19
- Last Posted Date
- 2015-10-28
- Lead Sponsor
- Orexo AB
- Target Recruit Count
- 668
- Registration Number
- NCT01903005
Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid Dependence
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-05-07
- Last Posted Date
- 2017-05-10
- Lead Sponsor
- Orexo AB
- Target Recruit Count
- 313
- Registration Number
- NCT01848054
Conversion From Fast Acting Oral Opioids to Abstral®
- First Posted Date
- 2011-03-15
- Last Posted Date
- 2017-04-05
- Lead Sponsor
- Orexo AB
- Target Recruit Count
- 8
- Registration Number
- NCT01315886
- Locations
- 🇸🇪
Smärtavdelning B42, Anestesikliniken Karolinska University Hospital, Huddinge, Stockholm, Sweden
© Copyright 2024. All Rights Reserved by MedPath